Reata (RETA) reports a wider-than-expected loss in the second quarter of 2022, while revenues miss estimates. Stock falls after updates on pipeline programs.
Whether it's thanks to a winning business model or timely good news, some companies are taking the bear market in stride, and some are even crushing it. Compared to the broader market's slump of around 5% in the last 12 months, AstraZeneca's (NASDAQ: AZN) stock has climbed 19%, making it a robust outperformer, to say the least. The company's success during the bear market is simply a matter of the strength of its drug development pipeline; with 184 projects in clinical trials and late-preclinical testing, it's among the largest in the world.
Some dividend stocks are better than others. The differentiator is how strong the underlying businesses are that make the dividends possible. We asked three Motley Fool contributors to pick unstoppable dividend stocks to buy in August.